A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
NCT07218146 · DLLEVATE Phase 3Recruiting
- Lead sponsor
- Zai Lab (Shanghai) Co., Ltd. (Industry)
- Enrollment
- 480 (estimated)
- Start date
- 30 Nov 2025
- Primary completion
- 30 Jun 2028 (estimated)
- Study completion
- 30 Nov 2028
- Last update posted
- 16 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- None
- Arms
- 2
Interventions
- ZL-1310 Drug
- Investigator's Choice of Therapy Drug
Conditions and primary outcome
- Small-cell Lung Cancer
Primary outcome
Confirmed objective response rate (ORR) assessed by Blinded Independent Central Review of ZL-1310 compared to Investigator's Choice Therapy (ICT) (up to 30 months); Overall survival of ZL-1310 compared to Investigator's Choice Therapy (ICT) (up to 30 months)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07218146.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07218146 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.